Artivion earnings release, May 7, 2026

Artivion, Inc. (AORT) · Form 8-K, Item 2.02 · Filed · SEC filing

Contacts:

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

First Quarter & Recent Business Highlights:

• Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis

• Net income for the first quarter of 2026 was $1.4 million, or $0.03 per fully diluted share, and non-GAAP net income was $4.2 million, or $0.08 per fully diluted share

• Adjusted EBITDA increased 26% to $22.1 million in the first quarter of 2026 compared to $17.5 million in the first quarter of 2025

• Announced U.S. FDA PMA Approval of the NEXUS Aortic Arch System for the treatment of aortic arch disease, including chronic aortic dissections

• Exercised option to acquire Endospan for an upfront purchase price of $135 million, net of previously extended loans

ATLANTA, GA – (May 7, 2026) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2026.

“In the first quarter of 2026, we achieved 12% constant currency revenue growth and 26% adjusted EBITDA growth, reflecting continued execution of our strategy to deliver long-term, profitable performance with an expanding and clinically differentiated product portfolio. Revenue results were driven by year-over-year gains in stent grafts of 21%, On-X of 20%, preservation services of 23%, BioGlue of 4%, all compared to the first quarter of 2025. On a constant currency basis, first quarter year-over-year stent grafts, On-X, and preservation services grew 10%, 17%, and 23%, respectively,” said Pat Mackin, Chairman, President, and Chief Executive Officer.

Page 1 of 11

Mr. Mackin continued, “We also continued to advance our best-in-class, aortic-focused product pipeline in the first quarter, driving strong enrollment in the ARTIZEN clinical trial. Further, we were pleased to see our partner Endospan receive U.S. FDA PMA approval for the NEXUS Aortic Arch System, ahead of our initial expectations. We have since exercised our option to acquire Endospan and expect the acquisition to close in the second quarter of 2026, subject to customary closing conditions. Our acquisition of the NEXUS system would expand our market-leading aortic arch portfolio, position us at the forefront of this segment, and broaden our pipeline with three additional PMA programs. With AMDS, NEXUS, and ultimately, Arcevo LSA, we stand to become the only company with a complete portfolio of aortic arch solutions.”

Mr. Mackin concluded, “While our first quarter performance fell short of our constant currency expectations due to some transient factors, we are confident that the fundamentals underpinning our strategy remain intact. We are seeing strong reordering behavior within AMDS accounts, which exceeded our expectations and reinforces our conviction in long-term adoption. Meanwhile, On-X continues to take share from both mechanical and bioprosthetic valves as the leading aortic valve on the market for patients under the age of 65.”

First Quarter 2026 Financial Results

Total revenues for the first quarter of 2026 were $116.3 million, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis, both compared to the first quarter of 2025.

Net income for the first quarter of 2026 was $1.4 million, or $0.03 per fully diluted common share, compared to net loss of $(0.5) million, or $(0.01) per fully diluted common share for the first quarter of 2025. Non-GAAP net income for the first quarter of 2026 was $4.2 million, or $0.08 per fully diluted common share, compared to non-GAAP net income of $2.5 million, or $0.06 per fully diluted common share, for the first quarter of 2025. Non-GAAP net income for the first quarter of 2026 includes pretax losses related to foreign currency revaluation of $0.8 million.

2026 Financial Outlook

Artivion has lowered its expectations for revenue for the full year 2026 and now expects revenue to be in the range of $480 to $496 million, representing growth of 7% to 11% on an adjusted constant currency basis compared to 2025 adjusted revenue¹. This compares to the previous range of $486 to $504 million, representing growth of 10% to 14% on an adjusted constant currency basis compared to 2025 adjusted revenue¹. This guidance contemplates currency to represent an approximate one percentage point tailwind for the full year.

Additionally, Artivion has lowered its expectations for adjusted EBITDA, and now expects adjusted EBITDA growth of between 12% and 20% for the full year 2026, compared to 2025, resulting in an expected range of $100 to $107 million for 2026. This compares to the previous range of between 18% and 22% compared to 2025, or an expected range of $105 to $110 million.

Full year 2026 adjusted EBITDA guidance excludes approximately $8 million of Endospan-related expenses expected to be incurred through full year 2026, contingent on closing. U.S. revenue attributable to NEXUS product sales is expected to be negligible for full year 2026 as the Company builds inventory and secures value analysis committee approvals ahead of a planned January 1, 2027 commercial launch.

The Company’s financial performance for 2026 and future periods is subject to the risks identified below.¹... (truncated)ears after 2018. See “Non-GAAP Financial Measures” for important information about our use of non-GAAP measures.

Page 2 of 11

Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, including non-GAAP adjusted revenue, non-GAAP net income, EBITDA, adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company’s non-GAAP adjusted constant currency growth rates compare current year revenues to prior period revenues adjusted for the impact of changes in currency exchange. The Company’s non-GAAP net income, EBITDA, adjusted EBITDA, general, administrative, and marketing, and free cash flows results primarily exclude (as applicable) depreciation and amortization expense, interest income and expense, non-cash compensation expense, loss or gain on foreign currency revaluation, income tax expense or benefit, expense/(income) for business development, integration, and severance, non-cash interest expense, capital expenditures, and other non-recurring items.

The Company generally uses non-GAAP financial measures to facilitate management’s review of the operational performance of the Company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions, the operating expense structure of the Company’s existing and acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines, and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and non-cash compensation expense. The Company believes it is useful to exclude this revenue impact and certain expenses from non-GAAP financial measures because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures.

The Company’s adjusted EBITDA expectations for fiscal 2026 exclude potential charges or gains that may be recorded during the fiscal year, relating to, among other things, non-cash compensation; expense/(income) for business development, integration, and severance; and foreign currency revaluations. The Company does not attempt to provide reconciliations of forward-looking adjusted EBITDA to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of the Company’s financial performance.

Webcast and Conference Call Information

The Company will hold a teleconference call and live webcast on May 7, 2026, at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session. To participate in the conference call dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13759187.

Page 3 of 11

The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations.

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with aortic diseases. Artivion’s four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenues:Products91,44278,798
Revenues:Preservation services24,89520,180
Revenues:Total revenues116,33798,978
Cost of products and preservation services:Products29,69725,263
Cost of products and preservation services:Preservation services11,19210,138
Cost of products and preservation services:Total cost of products and preservation services40,88935,401
Cost of products and preservation services:Gross margin75,44863,577
Operating expenses:General, administrative, and marketing60,82054,704
Operating expenses:Research and development8,8416,728
Operating expenses:Total operating expenses69,66161,432
Operating expenses:Operating income5,7872,145
Operating expenses:Interest expense5,3677,663
Operating expenses:Interest income-205-144
Operating expenses:Other expense (income), net286-3,079
Operating expenses:Income (loss) before income taxes339-2,295
Operating expenses:Income tax benefit-1,078-1,790
Operating expenses:Net income (loss)1,417-505
Income (loss) per shareBasic0.03-0.01
Income (loss) per shareDiluted0.03-0.01
Weighted-average common shares outstanding:Basic48,07442,232
Weighted-average common shares outstanding:Diluted49,73142,232
Weighted-average common shares outstanding:Net income (loss)1,417-505
Other comprehensive (loss) income:Foreign currency translation adjustments, net of tax-8,8466,331
Other comprehensive (loss) income:Comprehensive (loss) income-7,4295,826

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Products:Aortic stent grafts44,39736,602
Products:On-X25,95121,574
Products:Surgical sealants18,80518,106
Products:Other2,2892,516
Products:Total products91,44278,798
Products:Preservation services24,89520,180
Products:Total revenues116,33798,978
Products:North America58,69547,793
Products:Europe, the Middle East, and Africa43,98637,045
Products:Asia Pacific8,6908,214
Products:Latin America4,9665,926
Products:Total revenues116,33798,978

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Reconciliation of net income (loss), GAAP and EBITDA, non-GAAP to adjusted EBITDA, non-GAAP:Net income (loss), GAAP1,417-505
Adjustments:Interest expense5,3677,663
Adjustments:Interest income-205-144
Adjustments:Income tax benefit-1,078-1,790
Adjustments:Depreciation and amortization expense6,3405,446
Adjustments:EBITDA, non-GAAP11,84110,670
Adjustments:Non-cash compensation8,4148,045
Adjustments:Business development, integration, and severance2,484-3,057
Adjustments:Cybersecurity incident-1,4784,746
Adjustments:Loss (gain) on foreign currency revaluation822-2,856
Adjustments:Adjusted EBITDA, non-GAAP22,08317,548

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
GAAP:Income (loss) before income taxes339-2,295
GAAP:Income tax benefit-1,078-1,790
GAAP:Net income (loss)1,417-505
GAAP:Diluted income (loss) per common share0.03-0.01
GAAP:Diluted weighted-average common shares outstanding49,73142,232
Reconciliation of income (loss) before income taxes, GAAP to adjusted income, non-GAAP:Income (loss) before income taxes, GAAP:339-2,295
Adjustments:Amortization expense3,9113,388
Adjustments:Business development, integration, and severance2,484-3,057
Adjustments:Non-cash interest expense315543
Adjustments:Cybersecurity incident-1,4784,746
Adjustments:Adjusted income before income taxes, non-GAAP5,5713,325
Adjustments:Income tax expense calculated at a tax rate of 25%1,393831
Adjustments:Adjusted net income, non-GAAP4,1782,494
Reconciliation of diluted income (loss) per common share, GAAP to adjusted diluted income per common share, non-GAAP:Diluted income (loss) per common share, GAAP:0.03-0.01
Adjustments:Amortization expense0.080.08
Adjustments:Business development, integration, and severance0.05-0.07
Adjustments:Non-cash interest expense0.010.01
Adjustments:Cybersecurity incident-0.030.11
Adjustments:Tax effect of non-GAAP adjustments-0.03-0.03
Adjustments:Effect of 25% tax rate-0.03-0.03
Adjustments:Adjusted diluted income per common share, non-GAAP0.080.06
Reconciliation of diluted weighted-average common shares outstanding GAAP to diluted weighted-average common shares outstanding, non-GAAP:Diluted weighted-average common shares outstanding, GAAP:49,73142,232
Adjustments:Effect of dilutive stock options and awards1,306
Adjustments:Diluted weighted-average common shares outstanding, non-GAAP49,73143,538

Balance Sheet

In Thousands

March 31, 2026 – (Unaudited)December 31, 2025
Current assets:Cash and cash equivalents55,76464,908
Current assets:Trade receivables, net91,87189,758
Current assets:Other receivables13,74913,921
Current assets:Inventories97,99592,427
Current assets:Deferred preservation costs53,41254,531
Current assets:Prepaid expenses and other44,72542,537
Current assets:Total current assets357,516358,082
Current assets:Goodwill251,660254,091
Current assets:Acquired technology, net120,001123,664

Cash Flow

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net cash flows from operating activities:Net income (loss)1,417-505
Adjustments to reconcile net income (loss) to net cash from operating activities:Depreciation and amortization6,3405,446
Adjustments to reconcile net income (loss) to net cash from operating activities:Non-cash compensation8,4148,045
Adjustments to reconcile net income (loss) to net cash from operating activities:Non-cash lease expense1,2971,226
Adjustments to reconcile net income (loss) to net cash from operating activities:Write-down of inventories and deferred preservation costs1,0621,312
Adjustments to reconcile net income (loss) to net cash from operating activities:Deferred income taxes-524
Adjustments to reconcile net income (loss) to net cash from operating activities:Change in fair value of contingent consideration1,740-2,830
Adjustments to reconcile net income (loss) to net cash from operating activities:Other537-2,891
Changes in operating assets and liabilities:Receivables-2,760-7,922
Changes in operating assets and liabilities:Inventories and deferred preservation costs-6,379-2,453
Changes in operating assets and liabilities:Prepaid expenses and other assets-1,286-327
Changes in operating assets and liabilities:Accounts payable, accrued expenses, and other liabilities-8,704-16,054
Changes in operating assets and liabilities:Net cash flows provided by (used in) operating activities1,154-16,953
Net cash flows from investing activities:Capital expenditures-8,003-3,638
Net cash flows from investing activities:Payments related to sale of non-financial assets-1,500
Net cash flows from investing activities:Payments for Endospan agreements-1,000
Net cash flows from investing activities:Net cash flows used in investing activities-10,503-3,638
Net cash flows from financing activities:Repayment of debt-66
Net cash flows from financing activities:Proceeds from exercise of stock options and issuance of common stock1,2504,181
Net cash flows from financing activities:Principal payments on short-term notes payable-577
Net cash flows from financing activities:Other-210-178
Net cash flows from financing activities:Net cash flows provided by financing activities4633,937
Net cash flows from financing activities:Effect of exchange rate changes on cash and cash equivalents-258884
Net cash flows from financing activities:Decrease in cash and cash equivalents-9,144-15,770
Net cash flows from financing activities:Cash and cash equivalents beginning of period64,90853,463
Net cash flows from financing activities:Cash and cash equivalents end of period55,76437,693

Cash Flow

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP:Net cash flows provided by (used in) operating activities1,154-16,953
Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP:Capital expenditures-8,003-3,638
Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP:Free cash flows, non-GAAP-6,849-20,591
Full release

Forward-Looking Statements

Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include, but are not limited to, our beliefs and expectations about... (truncated)ected product mix and business strategy; anticipated quarterly fluctuations in our business; our ability to scale our business and expand adjusted EBITDA margins; that our revenues for the full year 2026 will be in the range of

$480 to $496 million, representing revenue growth of between

7% to 11

% compared to 2025 on an adjusted constant currency basis; that we expect non-GAAP adjusted EBITDA to increase between

12% and 20% for the full year 2026 compared to 2025, resulting in non-GAAP adjusted EBITDA in the range of

$100 to $107 million in 2026; estimated timing of closing on our planned acquisition of Endospan and the expected benefits to be achieved therefrom; and our expected expenses to be incurred after close.

These forward-looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including, but not limited to, the unpredictability of the timing and outcome of regulatory decisions and other regulatory developments; risks relating to our international operations; the benefits anticipated from the Ascyrus Medical LLC and Endospan transactions; the benefits anticipated from our clinical trials may not be achieved or achieved on our anticipated timelines; and the benefits anticipated from our expansion into APAC and LATAM may not be achieved or achieved on our anticipated timelines. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2025. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

Page 4 of 11

Artivion, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income

In Thousands, Except Per Share Data

(Unaudited)

Page 5 of 11

Artivion, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

In Thousands

Page 6 of 11

Artivion, Inc. and Subsidiaries

Condensed Consolidated Statement of Cash Flows

In Thousands

(Unaudited)

Page 7 of 11

Artivion, Inc. and Subsidiaries

Financial Highlights

In Thousands

(Unaudited)

Page 8 of 11

Artivion, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP

Revenues

$ In Thousands

(Unaudited)

Page 9 of 11

Artivion, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP

General, Administrative, and Marketing Expense, EBITDA, Adjusted EBITDA, and Free Cash Flows

In Thousands

(Unaudited)

Page 10 of 11

Artivion Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP

Net Income and Diluted Income Per Common Share

In Thousands, Except Per Share Data

(Unaudited)

Page 11 of 11

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Artivion earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.